I-Mab IMAB

NAS: IMAB | ISIN: US44975P1030 14/11/2024

1,070 USD (+2,88%)

(+2,88%) 14/11/2024

Grafiek I-Mab

Grafiek I-Mab

1 dag1d 2,88%
1 week1w -2,73%
1 maand1m -20,15%
3 maanden3m -2,73%
6 maanden6m -41,21%
1 jaar1j -37,79%
5 jaar5j -91,44%

I-Mab in het nieuws

Toon enkel gratis nieuws

10 september 2024 · I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer · Persbericht

28 augustus 2024 · I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates · Persbericht

26 augustus 2024 · I-Mab to Participate at the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

14 augustus 2024 · I-Mab to Release 1H 2024 Financial Results on August 28, 2024 · Persbericht

7 augustus 2024 · I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC) · Persbericht

15 juli 2024 · I-Mab Announces Leadership Transitions · Persbericht

6 juni 2024 · I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer · Persbericht

5 juni 2024 · I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers · Persbericht

22 mei 2024 · I-Mab to Participate at the Jefferies Global Healthcare Conference · Persbericht

30 april 2024 · I-MAB Filed 2023 Annual Report on Form 20-F · Persbericht

Profiel I-Mab

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Werknemers: 141

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe